KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.

Jill Corre, Laure Vincent, Philippe Moreau, Benjamin Hebraud, Cyrille Hulin, Marie C Béné, Annemiek Broijl, Denis Caillot, Michel Delforge, Thomas Dejoie, Thierry Facon, Jérôme Lambert, Xavier Leleu, Margaret Macro, Aurore Perrot, Sonja Zweegman, Thomas Filleron, Bastien Cabarrou, Niels W C J van de Donk, Sabrina Mahéo, Winnie Hua, Jianping Wang, Maria Krevvata, Véronique Vanquickelberghe, Carla de Boer, Alba Tuozzo, Fredrik Borgsten, Melissa Rowe, Robin Carson, Soraya Wuilleme, Pieter Sonneveld

Blood 146(6) 679-692

PMID40127397
PMCIDPMC13292241
DOI10.1182/blood.2024027620
发表日期2025-03-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance vs observation in transplant-eligible, newly diagnosed multiple myeloma. Here, we present long-term MRD status and PFS outcomes after a median follow-up of 80.1 months. Patients were randomly assigned (1:1) to daratumumab plus VTd (D-VTd) or VTd induction/consolidation; patients remaining on study were rerandomized to daratumumab maintenance or observation for ≤2 years. MRD status was assessed at predefined time points during each study phase. D-VTd improved overall MRD-negativity rates (10-5) after induction (34.6% vs 23.1%) and consolidation (63.7% vs 43.7%) and provided PFS benefit, regardless of postinduction MRD status, vs VTd alone. Daratumumab maintenance improved overall MRD-negativity rates over observation, regardless of induction/consolidation treatment (D-VTd/daratumumab vs D-VTd/observation, 10-5 [77.3% vs 70.7%] and 10-6 [60.7% vs 52.0%]; VTd/daratumumab vs VTd/observation, 10-5 [70.9% vs 51.2%] and 10-6 [48.4% vs 30.7%]) and improved MRD-negativity rates, regardless of risk status, as defined by cytogenetic abnormalities or the revised International Staging System score. Furthermore, daratumumab maintenance provided PFS benefit vs observation, regardless of induction/consolidation treatment and postconsolidation MRD status. D-VTd followed by daratumumab maintenance consistently produced the highest landmark, cumulative, and sustained MRD-negativity rates (10-5 and 10-6), translating to superior long-term PFS outcomes. These results demonstrate that daratumumab-based induction/consolidation followed by daratumumab maintenance resulted in the deepest and most durable MRD negativity, leading to superior PFS outcomes. This trial was registered at www.clinicaltrials.gov as #NCT02541383.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 5.

PFS according to MRD postinduction. Landmark analysis of PFS based on postinduction MRD status (MFC; 10 −5 ) in the ITT population overall (A) and by treatment arm (B). MRD−, MRD negative; MRD+, MRD positive.

A

PFS

Figure 5. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

PFS

Figure 5. · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 3:extreme upward reversal曲线 4:extreme upward reversal
查看结果
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Rates of MRD negativity. Rates of MRD negativity after induction and consolidation in the ITT population (10 −5 ) (A) and at any time during maintenance and follow-up in the maintenance ITT population (10 −5 and 10 −6 ) (B). MRD-negativity rates at 10 −5 after induction and consolidation are based on MFC; MRD-negativity rates at 10 −5 during maintenance and follow-up are based on NGS + MFC; MRD-negativity rates at 10 −6 are based on NGS only. DARA, daratumumab maintenance; OBS, observation.
非 KM Figure
Figure 2.Sustained MRD negativity rates. Rates in the maintenance ITT population over time of sustained MRD negativity (A) and CR or better plus sustained MRD negativity (B). MRD-negativity rates at 10 −5 are based on NGS + MFC; MRD-negativity rates at 10 −6 are based on NGS only. DARA, daratumumab maintenance; OBS, observation.
非 KM Figure
Figure 3.MRD negativity rates during maintenance. Landmark rates in the maintenance ITT population at defined time points during maintenance of MRD negativity (A) and CR or better plus MRD negativity (B). MRD-negativity rates at 10 −5 are based on NGS + MFC; MRD-negativity rates at 10 −6 are based on NGS only. DARA, daratumumab maintenance; OBS, observation.
非 KM Figure
Figure 4.Cumulative rates of MRD negativity. Cumulative rates in the maintenance ITT population over time of MRD negativity (A) and CR or better plus MRD negativity (B). MRD-negativity rates at 10 −5 are based on NGS + MFC; MRD-negativity rates at 10 −6 are based on NGS only. DARA, daratumumab maintenance; FU, follow-up; OBS, observation; PD, progressive disease.
非 KM Figure
Figure 6.PFS according to treatment arms. Landmark PFS analysis from second randomization in the maintenance ITT population based on postconsolidation MRD status (NGS; 10 −5 ) for DARA vs OBS overall (regardless of induction/consolidation treatment) (A), in the D-VTd treatment arm (B), and in the VTd treatment arm (C). DARA, daratumumab maintenance; MRD−, MRD negative; MRD+, MRD positive; OBS, observation.
非 KM Figure
Figure 7.PFS analysis from second randomization in the maintenance ITT population based on cytogenetic risk status, regardless of induction/consolidation treatment. DARA, daratumumab maintenance; OBS, observation; std, standard.
非 KM Figure